Photomedex traded down 3.69% on Friday, hitting $17.51. Photomedex has a 52-week low of $8.14 and a 52-week high of $16.81. The company’s market cap is $321.1 million.
A number of other analysts have also recently weighed in on PHMD. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of Photomedex in a research note to investors on Friday. Separately, analysts at BWS Financial initiated coverage on shares of Photomedex in a research note to investors on Monday, April 23rd. They set a “buy” rating and a $27.00 price target on the stock.
Photomedex Inc. is a Global Skin Health Solutions company that provides integrated disease management and aesthetic solutions through laser and light-based devices, pharmaceuticals and cosmeceuticals.